Atremorine in Parkinson’s disease: From dopaminergic neuroprotection to pharmacogenomics

Atremorine in Parkinson’s disease: From dopaminergic neuroprotection to pharmacogenomics
Med Res Rev. 2021 Jun 9. doi: 10.1002/med.21838. Online ahead of print.ABSTRACTAtremorine is a novel bioproduct obtained by nondenaturing biotechnological processes from a genetic species of Vicia faba. Atremorine is a potent dopamine (DA) enhancer with powerful effects on the neuronal dopaminergic system, acting as a neuroprotective agent in Parkinson's disease (PD). Over 97% of PD patients respond to a ... read more
Source: PubMedPublished on 2021-06-09By Ramón Cacabelos